Relevance.  Cervical cancer – one of malignant new growths most often met among women. Intraepithelial changes precede to it; these changes can disappear spontaneously or progress to cancer. For the present moment, there are no markers describing the outcome of cervical intraepithelial neoplasia. The  objective  was to research the expression L1 HPV and NuMA1 as factors of prognosis HPV-positive cervical intraepithelial neoplasias by high-risk human papillomavirus. Material and methods.  The biopsies of 178 women from HPV-positive cervical neoplasias were studied by cytological, histological, immunocytochemical methods and PCR. Results.  We verified HPV-HR-positive: mild (42.7 %), moderate (34.27 %), severe (21.91 %) dysplasias, Ca in situ (1.12 %). In 81.13 % of researches, CIN with expression of L1 and NuMA1 had regression of dysplasia, in 13.21 % – persistence of grade squamous intraepithelial lesion, in 5.66 % – progression of dysplasia. In 73.33 % of cases, CIN with expression of NuMA1 had regression, in 26.67 % – persistence of dysplasia. In 45.45 % of researches, CIN with expression of L1 had regression of dysplasia, in 48.48 % – persistence of grade squamous intraepithelial lesion, in 6.06 % – progression of dysplasia. Regression or progression of dysplasia with expression L1 and NuMA1 or one of these proteins for the first time was revealed later 6 months. Conclusion.  CIN could come to the end with regression, persistence or progression. At expression of atypical cells L1 and NuMA1, the greatest quantity – 81.13 %, of cases of CIN regression was noted. At expression of atypical cells only NuMA1, CIN came to the end with regression or long persistence. Course of CIN with expression L1 HPV was characterized by the greatest parameters of persistence and progression marked, accordingly, in 48.48 and 6.06 % of cases.

Ovarian cancer is one of the most aggressive malignant tumors in women. The role of hormone therapy in the treatment for ovarian cancer is not fully studied up to now. The literature contains data on the efficacy and safety of treatment with antiestrogens and aromatase inhibitors for recurrent ovarian cancer. The article summarizes the epidemiology, preclinical and clinical studies related to the role of estrogen and aromatase expression in this disease as well as the role of aromatase inhibitors in the treatment for ovarian cancer.

Abstract. The cytological evidence of cervical squamous epithelium lesions associated with HPV infection was identified as the presence of koilocytes in 16% of patients and atypical multicore cells with core and/or cytoplasm dystrophy of para-basal layer cells in 46%. The high grade squamous intraepithelial lesions were associated with the presence of HPV 16 mostly in combination with other high risk HPV genotypes.

Sixty 60 human papillomavirus (HPV) type 16-positive cervical epithelium biopsy specimens were studied by cytological, histological, immunomorphological, and PCR assays. No correlation was found between proliferation markers and the degree of integration of HPV 16 DNA integration into the cell genome. The number of cells with Ki-67 expression, mitoses, and their alteration was related to the grade of epithelial lesion. Expression of p53 was detected only in the episomal form of HPV DNA and its low integration.

The authors present an analysis of specific features of transfusions of erythrocyte containing media in oncological patients. Special attention was given to necessary selection of donor erythrocytes in performing operations with massive intraoperative blood loss. It considerably contributes to a decreased number of posttransfusional reactions and complications. For the recent five years transfusions of erythrocyte containing media to more than 15 thousand patients with surgical treatment were analyzed. Among them the individual selection of donor blood was fulfilled in 2047 cases. Compatible erythrocytes could not be selected in five cases only. In these patients infusions of Perftoran were used as an oxygen carrier both during operation and at the postoperative period.